Andy Pasternak - 04 Nov 2021 Form 4 Insider Report for Horizon Therapeutics Public Ltd Co (HZNP)

Signature
/s/ Miles W. McHugh, Attorney-in-Fact
Issuer symbol
HZNP
Transactions as of
04 Nov 2021
Transactions value $
$-2,723,811
Form type
4
Filing time
05 Nov 2021, 17:00:26 UTC
Previous filing
03 Nov 2021
Next filing
08 Dec 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HZNP Ordinary Shares Options Exercise $686,370 +23,251 +76.8% $29.52 53,523 04 Nov 2021 Direct
transaction HZNP Ordinary Shares Sale $-606,750 -5,484 -10.2% $110.64 48,039 04 Nov 2021 Direct F1, F2
transaction HZNP Ordinary Shares Sale $-706,274 -6,336 -13.2% $111.47 41,703 04 Nov 2021 Direct F1, F3
transaction HZNP Ordinary Shares Sale $-304,263 -2,706 -6.49% $112.44 38,997 04 Nov 2021 Direct F1, F4
transaction HZNP Ordinary Shares Sale $-641,501 -5,650 -14.5% $113.54 33,347 04 Nov 2021 Direct F1, F5
transaction HZNP Ordinary Shares Sale $-312,329 -2,728 -8.18% $114.49 30,619 04 Nov 2021 Direct F1, F6
transaction HZNP Ordinary Shares Sale $-839,065 -7,264 -23.7% $115.51 23,355 04 Nov 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HZNP Stock Option (Right to Buy) Options Exercise $0 -23,251 -50% $0.000000 23,251 04 Nov 2021 Ordinary Shares 23,251 $29.52 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.985 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.005 to $111.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.00 to $112.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.07 to $114.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.24 to $115.12 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The stock option is fully vested and exercisable.